Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
EditorialEditorial

APOL1 Gene — Implications for Systemic Lupus Erythematosus

LINDA T. HIRAKI
The Journal of Rheumatology August 2020, 47 (8) 1155-1157; DOI: https://doi.org/10.3899/jrheum.200038
LINDA T. HIRAKI
Pediatrics and Epidemiology, Dalla Lana School of Public Health, University of Toronto, and Clinician Scientist, Division of Rheumatology, and Scientist, Child Health Evaluative Sciences and Genetics and Genome Biology, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.
Roles: Assistant Professor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Linda.hiraki@sickkids.ca
  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

It is well recognized that African Americans of sub-Saharan African ancestry have nearly a 4-fold increased prevalence of endstage kidney disease (ESKD) over European Americans1,2,3,4. In 2008, two coding alleles in the apolipoprotein L1 gene (APOL1), G1 and G2, were discovered to account for the majority of excess risk in progressive nondiabetic kidney disease in African Americans1,2,3,5. The several forms of APOL-1–associated kidney disease include focal segmental glomerulosclerosis (FSGS), human immunodeficiency virus–associated nephropathy (HIVAN), hypertension-attributed ESKD, and sickle cell nephropathy5,6,7,8. There is a strong biallelic effect observed such that a high-risk genotype defined as the presence of 2 APOL1 risk alleles confers the strongest risk for HIVAN in the United States7 with an OR of 29 (95% CI 13–68), and an OR of 89 (95% CI 18–912) in South Africa9. This observation of stronger adverse kidney outcomes associated with APOL1 risk alleles was the rationale for a report by Vajgel, et al10 that appears in this issue of The Journal.

Their study involved genotyping APOL1 G1 and G2 risk alleles in 201 nonwhite Brazilian patients with lupus nephritis (LN) and 222 healthy blood donors. Because of the low APOL1 biallelic frequency in LN cases (2%), the authors had limited power to test biallelic effects and instead examined monoallelic APOL1 risk allele effect on LN outcomes. The authors observed a higher prevalence of LN patients with lower estimated glomerular filtration rates (eGFR; chronic kidney disease stages 4 and 5) of persistent duration (> 6 mos) in those with 1 APOL1 risk allele compared to those with none10.

The Vajgel, et al findings are consistent with prior studies of APOL1 risk allele effects on LN renal functional outcomes. In a study of 855 African American systemic lupus erythematosus (SLE) patients with LN-ESKD and 534 African American SLE patients without nephritis, APOL1 high-risk genotype was associated with progression to ESKD, with an OR 2.72 (95% CI 1.76–4.19, p = 6.23 × 10−6)3. That study also reported a shorter time from SLE onset to ESKD among those with an APOL1 high-risk genotype (5.5 ± 6.1 yrs) compared to those with 1 or no risk alleles (7.9 ± 7.3 yrs, p = 0.01)3. Yet Vajgel, et al’s study10, and other studies, observed no association between APOL1 risk alleles and LN risk itself, assuming sufficient power to detect an effect on LN risk similar to that on ESKD11,12.

In African Americans, the APOL1 risk allele frequency is about 36% and the prevalence of the high-risk APOL1 genotype is 13%6,13. In the Brazilian nonwhite population studied by Vajgel, et al, the APOL1 risk allele frequency was 9% among patients with LN, and 8% among non-SLE controls (p = 0.44). This high frequency of alleles with large effects suggests that natural selection for the beneficial APOL1 effects is at play. Circulating APOL1 likely kills the trypanosome by lysis14. This includes the parasite Trypanosoma brucei rhodesiense causing trypanosomiasis (African sleeping sickness), which evolved to develop a virulence factor, serum-resistant activity (SRA). SRA binds to and inactivates APOL1, enabling the parasite to escape the human, host defenses and survive. High-risk APOL1 genetic variants result in an encoded APOL1 protein, protected from SRA binding, providing a selective advantage4,13.

The high frequency of APOL1 GI and G2 alleles is also in part due to incomplete penetrance of their deleterious renal effects. Most people carrying the high-risk genotype never develop significant kidney disease4,7. This observation along with the recognition that APOL1 progressive CKD spans different systemic diseases suggests the possibility of a “2-hit” pathogenic process4. A potential second hit interacting with APOL1 risk genotype may be systemic disease such as HIV or SLE15.

Both HIV infections and SLE are diseases characterized by elevated type I interferon (IFN). HIV is a potent inducer of IFN and other innate antiviral immune responses. SLE is a type I IFN-driven autoimmune disease. There have also been reports of FSGS patients with a high-risk APOL1 genotype, treated with IFN, who developed collapsing glomerulopathy15. In 2019 there was a case report of an African American boy with SAVI (stimulator of IFN genes–associated vasculopathy with onset in infancy) — a disease of endogenous overproduction of type I IFN, APOL1 high-risk genotype, and collapsing glomerulopathy. These reports all implicate IFN as the common, key link between APOL1 and collapsing glomerulopathy16.

The most extreme histologic manifestation of APOL1-associated nephropathy is collapsing glomerulopathy. First described in HIVAN, this aggressive lesion is characterized by segmental or global collapse and sclerosis of the glomerular tufts, with clinical manifestations of nephrotic syndrome, renal insufficiency, and rapid progression to ESKD13. There are an increasing number of reports of collapsing glomerulopathy in LN, in the absence of infection17. Some of these reports make the link between APOL1 high-risk genotype and collapsing glomerulopathy in SLE18,19. One study identified 26 cases of collapsing glomerulopathy among 546 renal biopsies from African American patients with SLE. They observed an OR 5.4 (95% CI 2.4–12.1) for developing collapsing glomerulopathy for the APOL1 high-risk genotype (p < 0.001) compared to 1 or no risk alleles18. In the Vajgel, et al paper, the small number of patients with collapsing glomerulopathy precluded examination of the APOL1 association in their Brazilian cohort10.

Prior studies have investigated the associations between chronic kidney disease, cardiovascular disease (CVD), and APOL1 risk haplotypes, with differing results. In a single-center cohort study of 113 African American patients with SLE, the APOL1 risk allele frequency was 40%, and the frequency of the high-risk genotype was 13%20. Using chart review to assess and create composite indices for CVD endpoints, they observed that atherosclerotic CVD (defined as abdominal aortic aneurysm, angina, carotid artery disease, myocardial infarction, coronary artery disease, peripheral vascular disease, stroke, or vascular calcifications on imaging) was present in 30% of the cohort. The study reported more prevalent atherosclerotic CVD in those with 1 or more APOL1 risk alleles, compared to those with none (OR 7.1, 95% CI 2.1–24.0, p = 0.002). Their models adjusted for smoking status, ESKD, body mass index, and hypertension. ESKD was present in 20% of those with a high-risk genotype, compared with 2–8% of those with 0 or 1 APOL1 risk alleles. In contrast, a large metaanalysis of 21,305 participants of African American ancestry, from 8 cohorts, did not find an association between APOL1 high-risk genotype (prevalence 13%) and incident CVD or all-cause mortality21. This was after accounting for multiple risk factors for CVD and death, including kidney function (eGFR). Overall, there is limited evidence for a direct effect of APOL1 risk alleles on CVD outcomes independent of kidney function.

In recent years, we have learned a great deal about the relationship between APOL1, SLE, and kidney disease. Future research focused on how this knowledge affects prevention, prognosis, and therapy offers hope for improved care and outcomes for people with SLE at high risk of APOL1-associated disease.

Footnotes

  • See APOL1 in lupus nephritis, page 1209

  • Dr. Hiraki is supported by research grants from the Canadian Institute of Health Research and The Arthritis Society.

REFERENCES

  1. 1.↵
    1. Kao WH,
    2. Klag MJ,
    3. Meoni LA,
    4. Reich D,
    5. Berthier-Schaad Y,
    6. Li M,
    7. et al.
    MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008;40:1185–92.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Kopp JB,
    2. Smith MW,
    3. Nelson GW,
    4. Johnson RC,
    5. Freedman BI,
    6. Bowden DW,
    7. et al.
    MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008;40:1175–84.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Freedman BI,
    2. Langefeld CD,
    3. Andringa KK,
    4. Croker JA,
    5. Williams AH,
    6. Garner NE,
    7. et al.
    End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol 2014;66:390–6.
    OpenUrlPubMed
  4. 4.↵
    1. Kruzel-Davila E,
    2. Wasser WG,
    3. Skorecki K
    . APOL1 nephropathy: a population genetics and evolutionary medicine detective story. Semin Nephrol 2017;37:490–507.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Tzur S,
    2. Rosset S,
    3. Shemer R,
    4. Yudkovsky G,
    5. Selig S,
    6. Tarekegn A,
    7. et al.
    Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 2010;128:345–50.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Genovese G,
    2. Friedman DJ,
    3. Ross MD,
    4. Lecordier L,
    5. Uzureau P,
    6. Freedman BI,
    7. et al.
    Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010;329:841–5.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Kopp JB,
    2. Nelson GW,
    3. Sampath K,
    4. Johnson RC,
    5. Genovese G,
    6. An P,
    7. Friedman D,
    8. et al.
    APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 2011;22:2129–37.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Lipkowitz MS,
    2. Freedman BI,
    3. Langefeld CD,
    4. Comeau ME,
    5. Bowden DW,
    6. Kao WH,
    7. et al.
    Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int 2013;83:114–20.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Kasembeli AN,
    2. Duarte R,
    3. Ramsay M,
    4. Mosiane P,
    5. Dickens C,
    6. Dix-Peek T,
    7. et al.
    APOL1 risk variants are strongly associated with HIV-associated nephropathy in black South Africans. J Am Soc Nephrol 2015;26:2882–90.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Vajgel G,
    2. Lima S,
    3. Santana D,
    4. Oliveira C,
    5. Costa D,
    6. Anderson P,
    7. et al.
    A single APOL1 nephropathy variant increases risk of advanced lupus nephritis in Brazilians. J Rheumatol 2020;47:1209–17.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Freedman BI,
    2. Edberg JC,
    3. Comeau ME,
    4. Murea M,
    5. Bowden DW,
    6. Divers J,
    7. et al.
    The non-muscle Myosin heavy chain 9 gene (MYH9) is not associated with lupus nephritis in African Americans. Am J Nephrol 2010;32:66–72.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Lin CP,
    2. Adrianto I,
    3. Lessard CJ,
    4. Kelly JA,
    5. Kaufman KM,
    6. Guthridge J,
    7. et al.
    Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis. Genes Immun 2012;13:232–8.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Friedman DJ,
    2. Pollak MR
    . Genetics of kidney failure and the evolving story of APOL1. J Clin Invest 2011;121:3367–74.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Friedman DJ
    . A brief history of APOL1: a gene evolving. Semin Nephrol 2017;37:508–13.
    OpenUrlPubMed
  15. 15.↵
    1. Nichols B,
    2. Jog P,
    3. Lee JH,
    4. Blackler D,
    5. Wilmot M,
    6. D’Agati V,
    7. et al.
    Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1. Kidney Int 2015;87:332–42.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Abid Q,
    2. Best Rocha A,
    3. Larsen CP,
    4. Schulert G,
    5. Marsh R,
    6. Yasin S,
    7. et al.
    APOL1-associated collapsing focal segmental glomerulosclerosis in a patient with stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy (SAVI). Am J Kidney Dis 2019 Oct 7 (E-pub ahead of print).
  17. 17.↵
    1. Salvatore SP,
    2. Barisoni LM,
    3. Herzenberg AM,
    4. Chander PN,
    5. Nickeleit V,
    6. Seshan SV
    . Collapsing glomerulopathy in 19 patients with systemic lupus erythematosus or lupus-like disease. Clin J Am Soc Nephrol 2012;7:914–25.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Larsen CP,
    2. Beggs ML,
    3. Saeed M,
    4. Walker PD
    . Apolipoprotein L1 risk variants associate with systemic lupus erythematosus-associated collapsing glomerulopathy. J Am Soc Nephrol 2013;24:722–5.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Kofman T,
    2. Narjoz C,
    3. Raimbourg Q,
    4. Loriot MA,
    5. Karras A,
    6. Roland M,
    7. et al.
    Collapsing glomerulopathy associated lupus in a black female with homozygous APOL1 mutation. Lupus 2012;21:1459–62.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Blazer A,
    2. Wang B,
    3. Simpson D,
    4. Kirchhoff T,
    5. Heffron S,
    6. Clancy RM,
    7. et al.
    Apolipoprotein L1 risk variants associate with prevalent atherosclerotic disease in African American systemic lupus erythematosus patients. PLoS One 2017;12:e0182483.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Grams ME,
    2. Surapaneni A,
    3. Ballew SH,
    4. Appel LJ,
    5. Boerwinkle E,
    6. Boulware LE,
    7. et al.
    APOL1 kidney risk variants and cardiovascular disease: an individual participant data meta-analysis. J Am Soc Nephrol 2019;30:2027–36.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 47, Issue 8
1 Aug 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
APOL1 Gene — Implications for Systemic Lupus Erythematosus
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
APOL1 Gene — Implications for Systemic Lupus Erythematosus
LINDA T. HIRAKI
The Journal of Rheumatology Aug 2020, 47 (8) 1155-1157; DOI: 10.3899/jrheum.200038

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
APOL1 Gene — Implications for Systemic Lupus Erythematosus
LINDA T. HIRAKI
The Journal of Rheumatology Aug 2020, 47 (8) 1155-1157; DOI: 10.3899/jrheum.200038
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Transfer from Pediatric to Adult Care Is Hardly Child’s Play
  • Real-world Evidence Needs Careful Interpretation
  • Relapsing Polychondritis and Large-vessel Vasculitis
Show more Editorial

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire